article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

Following initial consultations in 2021, we expect the publication of the proposal for changes to the EU’s pharmaceutical legislation and potential adoption by the European Commission (EC) by December 2022. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2004. OHE Consulting Report [Internet].

article thumbnail

EU proposes new blood, tissues and cells Regulation

European Pharmaceutical Review

The proposal is a result of a comprehensive revision of the existing EU legislation, including the consultation of a wide range of BTC stakeholders and international organisations, such as the European Directorate for the Quality of Medicines & HealthCare (EDQM) of the Council of Europe.

Safety 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Pharma Marketing Pioneer, Sander Flaum, Passed Away

Contrarian Sales Techniques

He then launched Flaum Navigators in 2004, which was a consultancy that sought to help clients embrace innovation in medical sales and marketing. In 1988, he transitioned to the agency side of the organization and became the CEO of Euro RSCG Becker. He earned his undergraduate and MBA degrees from The Ohio State University.

article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

In addition, she worked as head of inspectorate and licensing for the MHRA from 2004-2006. In addition to site assessments, if marketing authorisations are to be acquired, activities to assess the currency of the data within those authorisations are important. About the author. She joined NSF in 2017.

Pharma 119
article thumbnail

The EU HTA regulation: a new frontier for access to innovative technologies

European Pharmaceutical Review

In addition, he was Head of the Legal Service at the European Medicines Agency from 2004 to 2012. Exactly how the Coordination Group will work has yet to be determined, but some considerations have already been made based on the regulation.

article thumbnail

Nitrosamines: the beginning of the end?

European Pharmaceutical Review

He is currently a CMC consultant with an interest in impurities and safety‑based limits. Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. Org Process Res Dev. 2023; 10.1021.acs.oprd.3c00008.

article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Lynne Byers, global managing director, Pharmaceuticals and Dietary Supplements Consulting, NSF. In addition, she worked as head of inspectorate and licensing for the MHRA from 2004-2006. Click here and here to check out parts 1 and 2 of this series, on GMP readiness and global supply chain issues. About the Author.